Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review

Schmidt‐Hansen, Mia; Bennett, Mike; Arnold, Sarah Louise; Bromham, Nathan; Hilgart, Jennifer

doi:10.1136/bmjspcare-2017-001457

Cited by 17 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of nausea was 20% to 27%, while the incidence of vomiting was 11.5% to 15%. 30,31 Recently, several studies have evaluated the effect of IV oxycodone on postoperative analgesia. Zhang et al 16 investigated the effect of oxycodone in patients undergoing open hepatectomy and reported that the incidence of PONV was approximately 35% when dexmedetomidine was combined perioperatively and 55% without dexmedetomidine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Intravenous Oxycodone Versus Sufentanil on the Incidence of Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery

Tao

Liu

Wang

et al. 2019

The Journal of Clinical Pharma

View full text Add to dashboard Cite

More than 30% of patients who undergo surgery will experience postoperative nausea and vomiting (PONV) if no prophylactic treatments are used. Although numerous studies have been performed to investigate the factors related to PONV, the effect of perioperative intravenous oxycodone on the incidence of PONV has not been well investigated. In this study, gynecological patients (grade I-II, aged 18-65 years, scheduled to undergo elective gynecological laparoscopic surgery under general anesthesia) were randomized to the oxycodone group or the sufentanil group. In the oxycodone group, patients received intravenous oxycodone for the induction and maintenance of anesthesia, as well as postoperative analgesia, while sufentanil was used in the sufentanil group. The primary outcome variable was the incidence of PONV. As secondary outcomes, time to first PONV, the rating of the most severe PONV, postoperative pain scores at different time points, hemodynamics, and side effects were evaluated. We found that, compared with sufentanil, oxycodone decreased the incidence of PONV by 13.5% (P = .041). The time to first vomiting was longer in the oxycodone group than in the sufentanil group. Postoperative pain scores at different time points and hemodynamics were comparable between the oxycodone and sufentanil groups. We concluded that the incidence of PONV in gynecological patients who underwent laparoscopic surgery was lower when using intravenous oxycodone for anesthesia induction, anesthesia maintenance, and postoperative analgesia than when using intravenous sufentanil. However, oxycodone and sufentanil provided the same stable hemodynamics during surgery and satisfactory postoperative analgesia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several studies have investigated the incidence of nausea and vomiting with oral oxycodone for cancer‐related pain control. The incidence of nausea was 20% to 27%, while the incidence of vomiting was 11.5% to 15% . Recently, several studies have evaluated the effect of IV oxycodone on postoperative analgesia.…”

Section: Discussionmentioning

confidence: 99%

Effect of Intravenous Oxycodone Versus Sufentanil on the Incidence of Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery

Tao

Liu

Wang

et al. 2019

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Recent Cochrane reviews found overall evidence that oxycodone provided similar analgesic and adverse effects to morphine, concluding that these agents could be interchangeable in the frontline treatment setting for cancer-related pain. 89,90 Studies of oxycodone/naloxone formulations showed effective analgesia with reduced opioid-induced constipation for long-term use in cancer-related pain. 91,92 Oxymorphone is an opioid agonist that acts primarily at the mu-opioid receptor.…”

Section: Codeinementioning

confidence: 99%

Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Swarm

Paice

Anghelescu

et al. 2019

Journal of the National Comprehensive Cancer Network

375

282

View full text Add to dashboard Cite

In recent years, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain have undergone substantial revisions focusing on the appropriate and safe prescription of opioid analgesics, optimization of nonopioid analgesics and adjuvant medications, and integration of nonpharmacologic methods of cancer pain management. This selection highlights some of these changes, covering topics on management of adult cancer pain including pharmacologic interventions, nonpharmacologic interventions, and treatment of specific cancer pain syndromes. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional aspects of this topic, including pathophysiologic classification of cancer pain syndromes, comprehensive pain assessment, management of pain crisis, ongoing care for cancer pain, pain in cancer survivors, and specialty consultations.

show abstract

“…However, experiments have suggested that the antinociceptive effect of oxycodone can be inhabited by selective µ-opioid receptor antagonists, such as β-funaltrexamine (β-FNA), but not by selective κ-opioid receptor antagonists [29,30]. Oxycodone has intravenous, subcutaneous, intramuscular, and oral formulations, and oral formulations includes immediate-release (IR) tablets (for 4-hourly dosing) and sustained (controlled-release (CR)) release tablets (for 12-hourly dosing) [31].…”

Section: Role Of Oxycodone Hydrochloride Prolonged-release Tablets Inmentioning

confidence: 99%

Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain

Wang

Xing

2020

Pain Research and Management

View full text Add to dashboard Cite

Radiotherapy is commonly used to treat cancer patients. Besides the curable effect, radiotherapy also could relieve the pain of cancer patients. However, cancer pain is gradually alleviated about two weeks after radiotherapy. In addition, cancer patients who receive radiotherapy may also suffer from pain flare or radiotherapy-induced side effects such as radiation esophagitis, enteritis, and mucositis. Pain control is reported to be inadequate during the whole course of radiotherapy (before, during, and after radiotherapy), and quality of life is seriously affected. Hence, radiotherapy is suggested to be combined with analgesic drugs in clinical guidelines. Previous studies have shown that radiotherapy combined with oxycodone hydrochloride can effectively alleviate cancer pain. In this review, we firstly presented the necessity of analgesia during the whole course of radiotherapy. We also sketched the role of oxycodone hydrochloride in radiotherapy of bone metastases and radiotherapy-induced oral mucositis. Finally, we concluded that oxycodone hydrochloride shows good efficacy and tolerance and could be used for pain management before, during, and after radiotherapy.

show abstract

Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review

Cited by 17 publications

References 34 publications

Effect of Intravenous Oxycodone Versus Sufentanil on the Incidence of Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery

Effect of Intravenous Oxycodone Versus Sufentanil on the Incidence of Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery

Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain

Contact Info

Product

Resources

About